A chemist by training who has decades of leadership experience in business development and business strategy, with a long-standing focus on oncology.
Jeb Keiper is the chief executive officer of Nimbus Therapeutics, a biotechnology company coupling targets selected based on causal human biology with structure-based drug discovery and development. He joined Nimbus in 2014 and oversaw finance, business development, IP, legal, PR and operations, prior to being appointed president and chief executive officer in October 2018. Since joining, Jeb has brought over $800m into Nimbus via partnerships and financing, including Nimbus’ Series B financing in March 2015, their exclusive licensing agreement with Genentech in 2015, the sale of Nimbus’ clinical NASH program to Gilead in May 2016 for $400m upfront, the strategic immunology alliance with Celgene announced in October 2017, a round of private expansion capital in 2018 and a second collaboration with BMS/Celgene in 2019. In April 2018, he was elected as an independent director to the board of Cardurion Pharmaceuticals, LLC, a clinical-stage cardiovascular diseases company based in Cambridge. Prior to Nimbus, Jeb was VP of business development at GSK Oncology and spent a decade at GSK in various BD leadership roles. He led the oncology portion of the GSK-Novartis 3-business swap for $16b announced in April 2014. Prior to GSK, Jeb was a consultant at McKinsey and worked in BD at TransForm Pharmaceuticals. Jeb began his career at Pfizer R&D as a bench chemist. He received four degrees from MIT; one in chemistry, two in chemical engineering and an MBA from MIT Sloan.